Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Erasca, Inc. stock logo
ERAS
Erasca
$13.61
-4.3%
$14.81
$2.75
▼
$24.28
$4.78B0.685.86 million shs11.01 million shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$56.42
-3.3%
$63.45
$56.18
▼
$90.87
$4.71B0.521.33 million shs950,205 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$48.13
-4.4%
$45.43
$38.02
▼
$61.76
$5.87B0.781.48 million shs2.06 million shs
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
$20.12
+2.0%
$21.30
$18.25
▼
$40.65
$1.39B0.65880,285 shs463,016 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Erasca, Inc. stock logo
ERAS
Erasca
+3.34%-9.89%-2.74%-19.34%+415.22%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-3.15%-7.94%-7.29%-16.46%-22.84%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
+4.94%+16.71%+21.78%-10.85%+26.91%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
+0.61%-0.15%-3.62%-24.26%+18.71%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Erasca, Inc. stock logo
ERAS
Erasca
$13.61
-4.3%
$14.81
$2.75
▼
$24.28
$4.78B0.685.86 million shs11.01 million shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$56.42
-3.3%
$63.45
$56.18
▼
$90.87
$4.71B0.521.33 million shs950,205 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$48.13
-4.4%
$45.43
$38.02
▼
$61.76
$5.87B0.781.48 million shs2.06 million shs
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
$20.12
+2.0%
$21.30
$18.25
▼
$40.65
$1.39B0.65880,285 shs463,016 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Erasca, Inc. stock logo
ERAS
Erasca
+3.34%-9.89%-2.74%-19.34%+415.22%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-3.15%-7.94%-7.29%-16.46%-22.84%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
+4.94%+16.71%+21.78%-10.85%+26.91%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
+0.61%-0.15%-3.62%-24.26%+18.71%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Erasca, Inc. stock logo
ERAS
Erasca
2.67
Moderate Buy$23.1770.22% Upside
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.73
Moderate Buy$99.2375.88% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
2.82
Moderate Buy$69.5044.40% Upside
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2.93
Moderate Buy$47.50136.08% Upside

Current Analyst Ratings Breakdown

Latest TYRA, SRRK, ERAS, and PTCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Initiated CoverageBuy$54.00 ➝ $55.00
11/17/2026
Erasca, Inc. stock logo
ERAS
Erasca
Initiated CoverageOutperform$35.00
11/12/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
DowngradeOutperform ➝ Peer Perform
11/11/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Boost Price TargetOutperform$53.00 ➝ $57.00
11/11/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Lower Price TargetBuy$29.00 ➝ $27.00
11/10/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Reiterated RatingStrong-Buy
11/2/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Boost Price TargetBuy$108.00 ➝ $109.00
10/30/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Boost Price TargetBuy$90.00 ➝ $95.00
10/30/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Boost Price TargetOverweight$109.00 ➝ $112.00
10/30/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Boost Price TargetSector Perform$75.00 ➝ $77.00
10/20/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Set Price Target$106.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/A$2.61 per shareN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$1.73B2.72$8.22 per share6.86($2.29) per share-24.64
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/A$1.38 per shareN/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/A$10.03 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Erasca, Inc. stock logo
ERAS
Erasca
-$124.55M-$0.99N/AN/AN/AN/A-31.63%-27.57%N/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$682.64M-$1.40N/A20.294.42-9.17%N/A-0.10%N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$377.94M-$3.36N/AN/AN/AN/A-175.27%-86.66%N/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$119.95M-$2.64N/AN/AN/AN/A-40.12%-37.62%N/A

Latest TYRA, SRRK, ERAS, and PTCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Erasca, Inc. stock logo
ERAS
Erasca
-$0.1301-$0.15-$0.0199-$0.15N/AN/A
11/10/2026Q3 2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.8472-$0.81+$0.0372-$0.81$0.30 million$0.57 million
11/10/2026Q3 2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$0.6687-$0.74-$0.0713-$0.74N/AN/A
10/29/2026Q3 2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.1434-$0.62-$0.7634-$0.62$306.43 million$357.81 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Erasca, Inc. stock logo
ERAS
Erasca
N/A
14.89
14.89
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
3.27
3.13
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
1.16
5.41
5.40
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/A
23.93
23.93

Institutional Ownership

CompanyInstitutional Ownership
Erasca, Inc. stock logo
ERAS
Erasca
67.78%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
84.14%

Insider Ownership

CompanyInsider Ownership
Erasca, Inc. stock logo
ERAS
Erasca
14.20%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5.30%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
10.30%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
12.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Erasca, Inc. stock logo
ERAS
Erasca
103350.96 million301.12 millionOptionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
99183.54 million79.12 millionOptionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
289122.00 million109.44 millionOptionable
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
8769.08 million60.45 millionOptionable

Recent News About These Companies

HC Wainwright Cuts Earnings Estimates for Tyra Biosciences
How Tyra Biosciences Inc. (TYRA) Affects Rotational Strategy Timing
Tyra Biosciences (NASDAQ:TYRA) Price Target Raised to $57.00
Tyra Biosciences' Q3 Net Loss Widens

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Erasca stock logo

Erasca NASDAQ:ERAS

$13.61 -0.61 (-4.29%)
Closing price 04:00 PM Eastern
Extended Trading
$13.83 +0.22 (+1.61%)
As of 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$56.42 -1.91 (-3.27%)
Closing price 04:00 PM Eastern
Extended Trading
$56.39 -0.03 (-0.05%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$48.13 -2.24 (-4.45%)
Closing price 03:58 PM Eastern
Extended Trading
$48.12 -0.01 (-0.02%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Tyra Biosciences stock logo

Tyra Biosciences NASDAQ:TYRA

$20.12 +0.39 (+1.98%)
Closing price 04:00 PM Eastern
Extended Trading
$20.09 -0.03 (-0.15%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.